Short Interest in DBV Technologies S.A. (NASDAQ:DBVT) Declines By 5.1%

DBV Technologies S.A. (NASDAQ:DBVT) saw a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 278,800 shares, a drop of 5.1% from the August 15th total of 293,700 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily volume of 50,900 shares, the short-interest ratio is presently 5.5 days.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. raised its position in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $0.74 on Wednesday. DBV Technologies has a 1 year low of $0.50 and a 1 year high of $2.97. The stock’s fifty day moving average price is $0.88 and its two-hundred day moving average price is $1.12. The company has a market cap of $71.60 million, a P/E ratio of -0.88 and a beta of 0.68.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The company had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period last year, the company posted ($0.26) EPS. On average, analysts expect that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on DBVT. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st. JMP Securities lifted their price objective on DBV Technologies from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Wednesday, July 31st. Finally, StockNews.com assumed coverage on shares of DBV Technologies in a report on Wednesday, September 11th. They set a “hold” rating on the stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.